Tango Therapeutics, Inc. (TNGX) Insider Trading
Over the last 3 months, TNGX insiders made 0 open-market buys and 5 sales, a net sale of -$2.2M (SEC Form 4). Over the last 6 months, 144 institutions increased and 85 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
5
Net (3m)
-$2.2M
Insider trades by month Buys Sells
Oct
Feb
Mar
Apr
May
Jun
Context3-month price +49.4%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Azelby Robertdirector | Grant | 5,740 | — |
| Jun 23, 2026 | Azelby Robertdirector | Grant | 35,910 | $27.97 |
| Jun 8, 2026 | Lee Sungdirector | Grant | 3,570 | $20.22 |
| Jun 8, 2026 | Ketchum John Bdirector | Grant | 4,000 | — |
| Jun 8, 2026 | Ketchum John Bdirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Calhoun Lesley Anndirector | Grant | 4,000 | — |
| Jun 8, 2026 | Calhoun Lesley Anndirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Rothenberg Macedirector | Grant | 4,000 | — |
| Jun 8, 2026 | Rothenberg Macedirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Lee Sungdirector | Grant | 570 | — |
| Jun 3, 2026 | Crystal Adamofficer: President, R&D | Option | 27,000 | $5.20 |
| Jun 3, 2026 | Crystal Adamofficer: President, R&D | Sell | 6,140 | $22.25 |
| Jun 3, 2026 | Crystal Adamofficer: President, R&D | Sell | 20,860 | $23.06 |
| May 5, 2026 | Crystal Adamofficer: President, R&D | Sell | 1,100 | $22.00 |
| May 5, 2026 | Gall Matthewofficer: Chief Financial Officer | Grant | 40,000 | — |
| May 5, 2026 | Gall Matthewofficer: Chief Financial Officer | Grant | 240,000 | $20.98 |
| May 5, 2026 | Crystal Adamofficer: President, R&D | Option | 27,000 | $5.20 |
| May 5, 2026 | Crystal Adamofficer: President, R&D | Sell | 25,900 | $21.19 |
| May 1, 2026 | Lee Sungdirector | Grant | 5,200 | $22.06 |
| May 1, 2026 | Lee Sungdirector | Grant | 12,300 | — |
| Apr 16, 2026 | Crystal Adamofficer: President, R&D | Sell | 38,460 | $25.00 |
| Apr 16, 2026 | Crystal Adamofficer: President, R&D | Option | 38,460 | $5.20 |
| Apr 2, 2026 | Crystal Adamofficer: President, R&D | Sell | 27,000 | $21.20 |
| Apr 2, 2026 | Crystal Adamofficer: President, R&D | Option | 27,000 | $5.20 |
| Mar 27, 2026 | Crystal Adamofficer: President, R&D | Sell | 12,000 | $20.11 |
| Mar 27, 2026 | Crystal Adamofficer: President, R&D | Option | 12,000 | $5.20 |
| Mar 9, 2026 | Crystal Adamofficer: President, R&D | Sell | 20,251 | $15.00 |
| Feb 27, 2026 | Crystal Adamofficer: President, R&D | Sell | 54,345 | $12.77 |
| Feb 4, 2026 | Weber Barbaradirector, officer: Director, Executive Chair | Grant | 37,522 | — |
| Feb 4, 2026 | Weber Barbaradirector, officer: Director, Executive Chair | Sell | 30,186 | $12.26 |
Source: TNGX SEC Form 4 filings, latest Jun 23, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their TNGX positions over the last 6 months (SEC Form 13F).
Increased
144
New positions
110
Reduced
85
Sold out
56
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| WOODLINE PARTNERS LP | Increased | 16.0M | May 15, 2026 |
| RTW INVESTMENTS, LP | Increased | 13.3M | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 13.1M | Feb 17, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 12.8M | May 15, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | Increased | 12.8M | Feb 17, 2026 |
| BOXER CAPITAL MANAGEMENT, LLC | Unchanged | 10.9M | May 15, 2026 |
| BOXER CAPITAL MANAGEMENT, LLC | Increased | 10.9M | Feb 17, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 10.8M | Feb 17, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 10.6M | Feb 17, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | Reduced | 10.5M | May 15, 2026 |
| BOXER CAPITAL MANAGEMENT, LLC | Unchanged | 10.4M | Feb 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 10.3M | May 15, 2026 |
| WOODLINE PARTNERS LP | Increased | 10.1M | Feb 17, 2026 |
| FMR LLC | Increased | 9.9M | May 15, 2026 |
| BOXER CAPITAL MANAGEMENT, LLC | Unchanged | 9.8M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.